Smadar Avigad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4985855/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. Leukemia, 2022, 36, 1759-1768.	7.2	4
2	Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species―and GSK3βâ€dependent mechanism. British Journal of Haematology, 2021, 192, 747-760.	2.5	8
3	Poorer outcome of childhood acute lymphoblastic leukemia in the Bedouin population: A report from the Berlinâ€Frankfurtâ€Muenster–based Israeli national protocols. Pediatric Blood and Cancer, 2020, 67, e28024.	1.5	2
4	SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS. Cancer Chemotherapy and Pharmacology, 2019, 83, 859-866.	2.3	2
5	EPEN-25. KANSL1 GAIN AND FUSION - A NOVEL ALTERATION IN CHILDHOOD EPENDYMOMA. Neuro-Oncology, 2018, 20, i78-i78.	1.2	0
6	Sporadic desmoid tumors in the pediatric population: A single center experience and review of the literature. Journal of Pediatric Surgery, 2017, 52, 1637-1641.	1.6	11
7	Prognostic relevance of miRâ€124â€3p and its target <i>TP53INP1</i> in pediatric ependymoma. Genes Chromosomes and Cancer, 2017, 56, 639-650.	2.8	16
8	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4030-E4039.	7.1	62
9	mi <scp>R</scp> expression profiling at diagnosis predicts relapse in pediatric precursor <scp>B</scp> â€cell acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2016, 55, 328-339.	2.8	32
10	New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B ell precursor acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 769-781.	2.5	44
11	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	16.8	933
12	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biology, 2015, 16, 133.	8.8	325
13	Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica, 2015, 100, 1442-1450.	3.5	65
14	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. Clinical Cancer Research, 2015, 21, 1904-1915.	7.0	80
15	The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. Oncotarget, 2015, 6, 33834-33848.	1.8	28
16	Potential role of WSB1 isoforms in growth and survival of neuroblastoma cells. Pediatric Research, 2014, 75, 482-486.	2.3	9
17	The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica, 2014, 99, e188-e192.	3.5	114
18	Prediction of Relapse By microRNA Expression in Pediatric B-Lineage Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3793-3793.	1.4	0

SMADAR AVIGAD

#	Article	IF	CITATIONS
19	Targeted Deep Sequencing of Genetic Alterations Identified By Whole Exome Sequencing Reveals Clonal Evolution in Pediatric T-Lymphoblastic Leukemia. Blood, 2014, 124, 491-491.	1.4	Ο
20	Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma. Epigenetics, 2013, 8, 1198-1204.	2.7	38
21	Minimal Residual Disease in Peripheral Blood Stem Cell Harvests From High-risk Neuroblastoma Patients. Journal of Pediatric Hematology/Oncology, 2009, 31, 22-26.	0.6	10
22	Novel approaches for the management of patients with Ewing sarcoma. Future Oncology, 2006, 2, 659-665.	2.4	3
23	Synovial sarcoma mimicking desmoplastic small round-cell tumor: Critical role for molecular diagnosis. , 2000, 34, 234-234.		2
24	A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene, 1997, 14, 1541-1545.	5.9	40
25	p53 mutation as the second event in juvenile chronic myelogenous leukemia in a patient with neurofibromatosis type 1. , 1997, 80, 2013-2018.		17
26	A single origin of phenylketonuria in Yemenite Jews. Nature, 1990, 344, 168-170.	27.8	68